A neutrophilic InflaMMation derIved marker as a predictor of iNfEctioN and exacerbaTion (IMMINENT)

Abstract

Individuals with cystic fibrosis (CF) experience chronic lung inflammation. This is due, in part, to abnormally high levels of neutrophils present in their lungs, releasing neutrophil elastase (NE), which damages lung tissue. Higher levels of NE in CF patients is associated with exacerbation, increased disease severity and increased likelihood of developing bronchiectasis. Excess levels of NE in the lung results in the cleavage of proteases. These cleaved protease fragments may be used as markers of NE activity in the airways and may act as biomarkers for inflammation, infection and/or bronchiectasis in CF.

Using Randox biochip technology, we will utilise the antibodies against these cleaved protease fragments as part of a near-patient immunodiagnostic test. Sputum and BAL samples from patients with CF, will be tested on these biochips and correlated to clinical parameters including microbiological and inflammatory data.

Thesis is embargoed until 31 December 2027.

Date of Award	Dec 2022
Original language	English
Awarding Institution	Queen's University Belfast
Sponsors	Northern Ireland Department for the Economy & Randox Laboratories Ltd
Supervisor	Cliff Taggart (Supervisor) & Sinead Weldon (Supervisor)